Jul 18, 2024 4:30 pm EDT Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
Jul 11, 2024 7:00 am EDT Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
May 14, 2024 7:30 am EDT Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
May 9, 2024 4:05 pm EDT Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
May 6, 2024 4:15 pm EDT Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Apr 22, 2024 4:15 pm EDT Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Apr 9, 2024 7:45 am EDT Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mar 7, 2024 4:05 pm EST Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Mar 4, 2024 4:30 pm EST Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference